Provided by Tiger Trade Technology Pte. Ltd.

CHINARES PHARMA

4.450
+0.0902.06%
Volume:9.13M
Turnover:40.55M
Market Cap:27.96B
PE:6.92
High:4.470
Open:4.380
Low:4.345
Close:4.360
52wk High:6.194
52wk Low:4.116
Shares:6.28B
HK Float Shares:6.28B
Volume Ratio:1.96
T/O Rate:0.15%
Dividend:0.24
Dividend Rate:5.49%
EPS(LYR):0.643
ROE:8.32%
ROA:2.64%
PB:0.45
PE(LYR):6.92
PS:0.09

Loading ...

China Resources Pharmaceutical Secures NAFMII Green Light for RMB5.00 Billion Medium-Term Note Programme

Bulletin Express
·
May 29

China Resources Pharma unit registers RMB 5 billion medium-term note programme in China

Reuters
·
May 29

CHINARES PHARMA to Distribute Final Dividend on August 3

Stock News
·
May 19

CHINARES PHARMA Declares HKD 0.139 Final Dividend for FY 2025; Ex-Dividend Date 17 June 2026

Bulletin Express
·
May 19

China Resources Pharmaceutical announces annual general meeting

Reuters
·
May 19

Global Bio-Chem unit wins Shenzhou Bio-tech order for 1,270 tonnes coenzyme Q10 mycelium

Reuters
·
May 08

China Resources Pharma unit CR Pharmaceutical Commercial posts Q1 net profit RMB 455.29 million

Reuters
·
Apr 30

China Resources Pharma unit CR Pharmaceutical Commercial issues RMB 1.4 billion bonds at 1.65%

Reuters
·
Apr 28

CR Pharmaceutical Commercial Completes RMB1.40 Billion Second-Tranche 2026 Bond Offering

Bulletin Express
·
Apr 28

CHINARES PHARMA Subsidiary Completes RMB 1.4 Billion Corporate Bond Issuance

Stock News
·
Apr 28

华润医药2025业绩稳健增长,聚焦研发及业务布局优化

Bulletin Express
·
Apr 28

CHINARES PHARMA Releases 2025 ESG Report: Revenue Up 4.6%, Carbon Intensity Down 20% from 2020

Bulletin Express
·
Apr 28

China Resources Pharma publishes 2025 sustainability report

Reuters
·
Apr 28

China Resources Pharmaceutical publishes 2025 annual report

Reuters
·
Apr 28

China Resources Pharma Shares Slump Over 5% Following Mixed Q1 Results From Subsidiaries

Stock News
·
Apr 27

Dong-E-E-Jiao's Profit Jumps 7% in Q1, Revenue Up 5.5%

MT Newswires Live
·
Apr 27

Stock Track | CHINARES PHARMA Plummets 5.02% Intraday on Subsidiary's Profit and Revenue Decline

Stock Track
·
Apr 27

CR Double-Crane's Profit, Revenue Fall in Q1

MT Newswires Live
·
Apr 27

CR Boya Bio-pharmaceutical Q1 2026: Revenue Down 40.1% YoY, Net Profit Drops 78.4%

Bulletin Express
·
Apr 24

China Resources Pharmaceutical - Cr Boya Bio-Pharmaceutical Qtrly Unaudited Revenue RMB 321.1 Mln, Net Profit RMB 30.0 Mln

THOMSON REUTERS
·
Apr 24